1. Prostate cancer, tumor immunity and a renewed sense of optimism in immunotherapy

   • Nicolò Rigamonti
   • Matteo Bellone

   Review 14 February 2012 Pages: 453 - 468

2. The aggressiveness of murine lymphomas selected in vivo by growth rate correlates with galectin-1 expression and response to cyclophosphamide

   • Mariano F. Zacarías Fluck
   • Leonardo Hess
   • O. Graciela Scharovsky

   Original article 27 September 2011 Pages: 469 - 480

   

3. Immunological effects of Taxol and Adryamicin in breast cancer patients

   • C. Panis
   • L. G. T. Lemos
   • R. Cecchini

   Original article 30 September 2011 Pages: 481 - 488

   

4. Recombinant human CD137L for cancer immunotherapy: effects of different fusions and linkers on its activity

   • Shuzhen Wang
   • Junfang Lv
   • Yijun Chen

   Original article 04 October 2011 Pages: 489 - 495

   

5. A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells

   • Archana Thakur
   • Dana Schalk
   • Lawrence G. Lum

   Original article 05 October 2011 Pages: 497 - 509

   

6. The small molecule TGF-β signaling inhibitor SM16 synergizes with agonistic OX40 antibody to suppress established mammary tumors and reduce spontaneous metastasis

   • Kendra Garrison
   • Tobias Hahn
   • Emmanuel T. Akporiaye

   Original article 05 October 2011 Pages: 511 - 521

   

7. Tipifarnib-mediated suppression of T-bet-dependent signaling pathways

   • Fanqi Bai
   • Alejandro V. Villagra
   • Pearlie Epling-Burnette

   Original article 09 October 2011 Pages: 523 - 533

   

8. Mycobacteria activate γδ T-cell anti-tumour responses via cytokines from type 1 myeloid dendritic cells: a mechanism of action for cancer immunotherapy

   • Daniel W. Fowler
   • John Copier
   • Mark D. Bodman-Smith

   Original article Open access 15 October 2011 Pages: 535 - 547

   

9. Intratumoral interleukin-2/agonist CD40 antibody drives CD4⁺-independent resolution of treated-tumors and CD4⁺-dependent systemic and memory responses

   • Connie Jackaman
   • Delia J. Nelson

   Original article 15 October 2011 Pages: 549 - 560

   

10. CpG or IFN-α are more potent adjuvants than GM-CSF to promote anti-tumor immunity following idiotype vaccine in multiple myeloma

    • Sungyoul Hong
    • Jianfei Qian
    • Qing Yi

    Original article 15 October 2011 Pages: 561 - 571

    

11. Therapeutic effect of intratumoral administration of DCs with conditional expression of combination of different cytokines

    • Chun Huang
    • Rupal Ramakrishnan
    • Dmitry I. Gabrilovich

    Short communication 06 January 2012 Pages: 573 - 579

    

12. The entirely carbohydrate immunogen Tn-PS A1 induces a cancer cell selective immune response and cytokine IL-17

    • Ravindra A. De Silva
    • Dananjaya K. Appulage
    • Peter R. Andreana

    Short Communication 02 February 2012 Pages: 581 - 585

    

13. First International Meeting of the Thematic Centre for Immune Modulatory Therapies for Autoimmunity and Cancer (IMTAC) 13–14 June 2011, Ljusterö, Sweden

    • Aniruddha Choudhury
    • Petter Höglund
    • Anders Österborg

    Meeting report 15 January 2012 Pages: 587 - 591

14. Acknowledgement

    Acknowledgement to Reviewers 09 March 2012 Pages: 593 - 597